EP2491025A1 - Composés d'aza-azulène - Google Patents

Composés d'aza-azulène

Info

Publication number
EP2491025A1
EP2491025A1 EP10769337A EP10769337A EP2491025A1 EP 2491025 A1 EP2491025 A1 EP 2491025A1 EP 10769337 A EP10769337 A EP 10769337A EP 10769337 A EP10769337 A EP 10769337A EP 2491025 A1 EP2491025 A1 EP 2491025A1
Authority
EP
European Patent Office
Prior art keywords
cancer
nmr
dmso
ppm
azaazulene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10769337A
Other languages
German (de)
English (en)
Other versions
EP2491025B1 (fr
EP2491025A4 (fr
Inventor
On Lee
Chih-Hung Chen
Chi-Y Hung
Yow-Lone Chang
Ting-Shou Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute ITRI
Original Assignee
Industrial Technology Research Institute ITRI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI filed Critical Industrial Technology Research Institute ITRI
Publication of EP2491025A1 publication Critical patent/EP2491025A1/fr
Publication of EP2491025A4 publication Critical patent/EP2491025A4/fr
Application granted granted Critical
Publication of EP2491025B1 publication Critical patent/EP2491025B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Definitions

  • the invention relates to a medicine, and in particular to azaazulene compounds which modulate the protein kinases (PKs) activity and/or treat cancer
  • PKs protein kinases
  • PKs Protein kinases
  • the PKs mediate cellular signal transduction in regulating cellular function such as proliferation, differentiation, growth, cell cycle, cell metabolism, cell survival, cell apoptosis, DNA damage repair, cell motility, and response to the micro environment
  • Deregulated PKs activity is a frequent cause of disease such as angiogenesis, cancer, tumor growth, tumor metastasis, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases and/or parasitical disease
  • the PKs can be divided into two classes the protein tyrosine kinases (PTKs) and the serine/threonine kinases (STKs) PTKs, which catalyze the transfer of the gamma- phosphate of ATP to tyrosine residues in protein substrates is one of the key covalent modifications that occurs in multi-cellular organisms as a result of intercellular communication during embryogenesis and maintenance of adult tissues Phosphorylation of tyrosine residues modulates enzymatic activity of PTKs and the recruitment of downstream signaling proteins
  • Two classes of PTKs are present in cells the transmembrane receptor PTKs and the nonreceptor PTKs PTKs are critical components of cellular signaling pathways, their catalytic activity is stnctly regulated Unregulated activation of these enzymes, through mechanisms such as point mutations or over- expression, can lead to various forms of cancer as well as benign proliferative conditions The importance of PTKs in health and disease is further underscore
  • the EGFR epidermal growth factor receptor
  • EGF transforming growth factor-beta
  • betacellulm heparin- binding EGF
  • epiregulin or amphiregulm
  • EGFR is over expressed in many types of tumor cells, such as bladder, lung, gastric, breast, brain, head & neck, cervix, ovary, endometrium, etc.
  • Abnormally high EGFR activity can be characteristic of non-small-cell lung cancers, breast cancers, ovarian cancers, bladder cancers, prostate cancers, salivary gland cancers, pancreatic cancers, endometrial cancers, colorectal cancers, kidney cancers, head and neck cancers, and glioblastoma multiforme
  • a tyrosine kinase inhibitor targeted to EGFR can be used for the treatment of cancers having abnormally high EGFR kinase activity and EFGR kinase disorder diseases
  • PDGFR platelet derived growth factor receptor
  • PDGFR platelet derived growth factor receptor
  • CSFIR CSFIR, c-KIT and c-fms. These receptors consist of glycosylated extracellular domains composed of variable numbers of immunoglobin-like loops and an intracellular domain wherein the tyrosine kinase domain is interrupted by unrelated amino acid sequences.
  • PDGFR signals induce expression of pro-angiogenic signals (including VEGF) in endothelial cells, further stimulating tumor angiogenesis.
  • the PDGFR signaling pathway may play an important role in cell proliferation, cell migration, and angiogenesis, and may mediate the high interstitial fluid pressure of tumors
  • Hk fetus liver kinase
  • This group is believed to be made up of kinase insert domam-receptor fetal liver kinase-1 (KDR/FLK-1 , VEGF-R2), flk-lR, flk-4 and fms-like tyrosine kinase 1 (flt-1)
  • KDR/FLK-1 domam-receptor fetal liver kinase-1
  • VEGF-R2 fetalk-lR
  • flk-4 fms-like tyrosine kinase 1
  • Abnormally high PDGFR activity can be characteristic of gastrointestinal stromal tumor, small cell lung cancer, glioblastoma multiforme, and prostate cancer
  • a tyrosine kinase inhibitor targeted to PDGFR can be used for the treatment of cancers having abnormally high PDGFR kinase activity and PDGFR kinas
  • FLT-3 FMS-like tyrosine kinase 3
  • CSFl colony stimulating factor 1
  • VEGFR ⁇ ascular endothelial growth factor receptor
  • VEGFR is a dimeric glycoprotein similar to PDGFR but has different biological functions and target cell specificity in vivo
  • VEGFR is presently thought to play an essential role is ⁇ asculogenesis and angiogenesis
  • Angiogenesis is essential for tumor growth and survival
  • VEGFR-I is thought to play a role in regulating VEGF binding to VEGFR-2 during angiogenesis
  • VEGFR-2 (KDR) stimulates the proliferation, migration, and survival of endothelial cells during angiogenesis and is recognized as a critical VEGF receptor for angiogenesis
  • VEGFR-3 stimulates the proliferation, migration, and survival of endothelial cells during lymphangiogenesis, which in turn facilitates metastases Despite these seemingly distinct
  • RET is a tyrosine kinase receptor whose ligands are neurotrophic factors of the ghal-cell line derived neurotrophic factor (GDNF) family, including GDNF, neurturm, artemm and persefm. RET activation is mediated via different glycosyl phosphatidylmositol-linked GRF receptors 3 main isoforms of RET is detected in human, such as long isoform (RET51): 1114 amino acids, middle isoform (RET 43): 1106 amino acids and short isoform (RET 9) 1072 ammo acids.
  • RET51 long isoform
  • RET 43 middle isoform
  • RET 9 1106 amino acids
  • RET 9 short isoform
  • RET is mamly expressed in tumors of neural crest origin, medullary thyroid carcinoma, pheochromocytoma and neuroblastoma. In human embryos, RET is expressed in a cranial population of neural crest cells, and in the developing nervous and urogenital systems RET expression is found in several crest- derived cell lines, spleen, thymus, lymph nodes, salivary glands, spermatogonia, and recently in normal thyroid tissue, thyroid adenoma and both papillary and follicular thyroid cell neoplasias.
  • a tyrosine kinase inhibitor targeted to RET can be used for the treatment of cancers having abnormally high RET kinase activity and RET kinase disorder diseases.
  • c-ABL v-abl Abelson murine leukemia viral oncogene homolog
  • NLS nuclear localization signals
  • NES single nuclear export signal
  • 3BPl binding protein
  • binding protein binds normal ABL on SH3 domain, which prevents SHI activation.
  • Nuclear and cytoplasmic ABL may have different functions. 1 -Nuclear c-ABL plays a major role in the regulation of cell death after DNA damage All DNA damage inducing agents activate nuclear c-ABL kinase in an ATM- dependent manner and in the presence of the p53-homolog p73 protein The latter is physically associated with c-ABL after DNA damage through the SH3 domain of c-ABL DNA damage also activates simultaneously p53 pathway, leading to the activation of Rb which induces growth arrest and protects cells from apoptosis The exact mechanisms of apoptosis induced b ⁇ c-ABL are unknown The nuclear entrapment of BCR-ABL has also been shown to induce apoptosis in leukemic cells 2-Cytoplasmic c-ABL possible function in adhesion signaling as an efflux of c-ABL from
  • TIE tyrosine kinase with lmmunoglobulm-like and EGF-like domains
  • TIE-I tyrosine kinase with Ig and EGF homology domains 1
  • TIE-2/Tek comprise a receptor tyrosine kinase (RTK) subfamily with unique structural characteristics two lmmunoglobuhn-like domains flanking three epidermal growth factor (EGF)-hke domains and followed by three fibronectm type Ill-like repeats in the extracellular region and a split tyrosine kinase domain in the cytoplasmic region
  • RTK receptor tyrosine kinase
  • RTK receptor tyrosine kinase
  • EGF epidermal growth factor
  • TIE-I cDNA encodes a 1124 ammo acid (aa) residue precursor protein with an 18 residue putative signal peptide
  • FGFR fibroblast growth factor receptors
  • FGFR fibroblast growth factor receptors
  • the fibroblast growth factors are the largest family of growth factor ligands comprising of 23 members FGFRs share a similar sequence structure, characterized by three extracellular lmmunoglobulin-hke domains (IgI, IgII, and IgIII), a single-pass transmembrane segment, and a split tyrosine kinase (TK1/
  • MAP mitogen activated protein
  • PI3K phosphotidyhnositol-3 -kinase
  • EGF epidermal growth factor
  • TrkA Tropomyosm-Related Kinase A
  • NGF Nerve Growth Factor
  • PTK disorder disease includes, such as cancer, asarthntis, diabetic retinopathy, restenosis, hepatic cirrhosis, atherosclerosis, angiogensis, glomerulonephritis, diabetic nephropathy, thrombic microangiopathy syndromes, transplant rejection, autoimmune disease, diabetes, and hyperimmune disorders
  • Cancers include, without limitation, carcinoma of the bladder, breast colon, kidney, liver, lung, head and neck, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, skm, hematopoietic tumor of lymphoid lineage (i e leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkm's lymphoma, non-Hodgkm's lymphoma, hairy cell lymphoma and Burkett's lymphoma),
  • One embodiment of the invention features azaazulene compounds of formula (I):
  • each of Ai, A 2 , A 3 , A 4 , A 5 , A 6 , A 7 . and A 8 independently, is carbon or nitrogen;
  • R 1 is O, OR, S, SR, NH2, NHR, NRR', NH, or NR; [0027] each Of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Rs, R9, R 10 , R 11 , R12, and R 13 , independently, is null.
  • H halo, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C1-C 20 heterocycloalkyl, C 1 -C 20 heterocycloalkenyl, C3-C20 aryl, C 1 -C 20 heteroaryl, NO 2 , NO, N 3 , SCN, CN, OCN, OR, OC(O)R, OC(S)R, OC(S)OR.
  • each of R, R', and R independently is H, halo, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C2-C10 alkynyl, C3-C 20 cycloalkyl, C3-C 20 cycloalkenyl, C 1 -C 20 heterocycloalkyl, C 1 -C 20 heterocycloalkenyl, C3-C 20 aryl, or C 1 -C 20 heteroaryl, or R and R-, R and R" or R" and R" together with the atom to which they are attached, are C 1 -C 20 heterocycloalkyl or C 1 -C 20 heterocycloalkenyl,
  • C N is C— N.
  • alkyl refers to a straight or branched hydrocarbon chain radical group having from one to twenty carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1 -dimethyl ethyl (t-but) l), and the like
  • alkenyl refers to a linear or branched hydrocarbon moiety that contains at least one double bond having from two to twenty carbon atoms and which is attached to the rest of the molecule by a single bond or a double bond, e g , ethenyl, prop-1- enyl, but-1-enyl, pent-1 -enyl, penta-1,4-dienyl, and the like
  • alkynyl refers to a linear or branched hydrocarbon moiety that contains at least one triple bond having from two to ten carbon atoms, and which is attached to the rest of the molecule by a single bond or a triple bond, e g , ethynyl, prop-1-ynyl, but- 1-ynyl, pent-1-ynyl, pent-3-ynyl and the like
  • cycloalkyl refers to a saturated, mono- bi- or tricjclic hydrocarbon moiety ha ⁇ ing from three to twenty carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond, e g , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decalinyl, norbornane, norbornene, adamantjl, bicyclo[2 2 2]octane and
  • heterocyclic moiety refers to a saturated, mono- bi- or tricyclic moiety having from one to twenty carbon atoms and at least one ring heteroatom (e g , N, O, or S), such as 4-tetrahydropyranyl
  • heterocycloalkenyl refers to a non-aromatic, mono- bi- or tricyclic moiety having from one to twenty carbon atoms and at least one ring heteroatom (e g , N, O, or S) and at least one double bond, such as pyranyl
  • aryl refers to a hydrocarbon moiety having from six to thirty carbon atoms and one or more aromatic rings Examples of aryl moieties include phenyl (Ph), phenyl ene, naphthyl, biphenyl, naphthylene, pyrenyl, anthryl, azulenyl, and phenanthryl.
  • heteroaryl refers to a moiety having from one to thirty carbon atoms and one or more aromatic rings that contain at least one heteroatom (e g . N, O, or S)
  • heteroaryl moieties include, but are not limited to, acridinyl, azaazulenyl, benzimidazolyl, benzindolyl, benzisoxazmyl, benzo[4,6]imidazo[1,2-a]pyridmyl, benzofuranyl, benzonaphthofuranyl, benzothiadiazolyl, benzothiazolyl, benzothiophenyl, benzotnazolyl, benzothiopyranyl, benzoxazmyl, benzoxazolyl, benzothiazolyl, beta - carbohnyl, carbazolyl.
  • pyrazolyl pyridazinyl, pyridinyl, pyridopyridinyl.
  • pyrimidinyl pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrazolyl, thiadiazolyl, thiazolyl, thiophenyl, triazinyl, and triazolyl.
  • Alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl. aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties, unless specified otherwise. Possible substituents on cycloalkyl, cycloalkenyl, heterocycloalkyl.
  • heterocycloalkenyl, aryl, and heteroaryl include, but are not limited to, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 3 -C 20 cycloalkyl, C 3 -C 20 cycloalkenyl, C 1 -C 20 heterocycloalkyl, C 1 -C 20 heterocycloalkenyl, C 1 -C 10 alkoxy, C 3 -C 30 aryl.
  • Another embodiment of the invention features a method for treating cancer
  • the method includes administering to a subject in need thereof an effective amount of one or more azaazulene compounds of formula (I) shown above
  • cancer include leukemia (e g , acute myelogenous leukemia), gastrointestinal cancer (e g , a gastrointestinal stromal tumor), kidney cancer (e g , metastatic renal cell carcinoma), or lung cancer (e g , small cell lung cancer)
  • the term '"treating" or “treatment” refers to administering one or more azaazulene compounds to a subject, who has an above-described disease, a symptom of such a disease, or a predisposition toward such a disease, with the purpose to confer a therapeutic effect, e g , to cure, relieve, alter, affect, ameliorate, or prevent the above- described disease, the symptom of it, or the predisposition toward it [0043]
  • Another embodiment of the invention encompasses a pharmaceutical composition that contains an effective amount of at least one of the above-mentioned azaazulene compound and a pharmaceutically acceptable carrier
  • the azaazulene compounds described above include the compounds themselves, as well as their salts, prodrugs, solvates, complexes, or radioisotope labeled derivatives, if applicable
  • a salt, for example, can be formed between an anion and a positivel> charged group (e g , amino) on an azaazulene compound Suitable an
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion
  • the azaazulene compounds also include those salts containing quaternary nitrogen atoms.
  • Examples of prodrugs include esters and other pharmaceutically acceptable derivatives, which, upon administration to a subject, are capable of providing active azaazulene compounds
  • a solvate refers to a molecule formed between an active azaazulene compound and a pharmaceutically acceptable solvent.
  • Examples of pharmaceutically acceptable solvents include water, ethanol, lsopropanol, ethyl acetate, acetic acid, and ethanolamine
  • a complex can be formed between an active azaazulene compound and a complexmg agent (e g , cyclodextrins or cyclophanes) or between an active azaazulene compound and an inorganic cation (e g , zinc, magnesium, calcium, silver, or copper cations).
  • a complexmg agent e g , cyclodextrins or cyclophanes
  • an inorganic cation e g , zinc, magnesium, calcium, silver, or copper cations
  • the cancer mentioned above may comprise acute myeloid leukemia (AML).
  • AML acute myeloid leukemia
  • the invention further provides a method of inhibiting the activity of protein kinase in a subject The method includes administering to a cell in need thereof an effective amount of one or more azaazulene compounds of formula (I) shown above.
  • protein kinase examples include AMPK, BLK, CSFlR, FGFR, FGR, FLT3, KDR, KIT, LCK, LYN, MAP4K5, NTRK, PHKGl, RET, SRC, STK, and YESl
  • the subject in the method of inhibiting the activity of protein kinase in a subject of the invention, the subject may be a cancer cell, and the cancer cell may comprise a cell of acute myeloid leukemia.
  • Fig 1 shows the mean tumor volumes of the MV4-11 subcutaneous tumor xenograft model in BALB/c mice after B26 or ⁇ ehicle administration
  • the azaazulene compounds in this invention can be prepared by methods well known in the art For example, the following schemes illustrate the typical synthetic routes for preparing the azaazulene compounds in this invention [0051]
  • the intermediates for constructing the azaazulene cores can be synthesized by following scheme
  • azaazulene compounds in this invention containing imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidme, imidazo[1.2-c]pyrimidine, imidazo[1,2-a]pyrazine and imidazo[1,2-a][l ,3,5]triazine type 6,5-fused heterocycles can be synthesized by following scheme
  • a base can be used to facilitate synthesizing the azaazulene compounds of the invention
  • the base is a compound containing a nitrogen atom, such as ammonia, methylamme, trimethyl amine, triethylamme, aniline, dimethylaminopyridme, proline, N-methylaniline, 1,8-diazabicyclo[5 4 0]undec-7-ene, diisopropylethylamme, pyrrolidine, piperidine, sodium amide, lithium d ⁇ sopropylamide, and sodium hexamethyldisilazanide.
  • a nitrogen atom such as ammonia, methylamme, trimethyl amine, triethylamme, aniline, dimethylaminopyridme, proline, N-methylaniline, 1,8-diazabicyclo[5 4 0]undec-7-ene, diisopropylethylamme, pyrrolidine, piperidine,
  • organic or inorganic bases can also be used in the reaction set forth in the above scheme
  • examples of organic or inorganic bases that do not contain a nitrogen atom include carbonates, bicarbonates, acetates, formates, alkyl lithium compounds, aryl lithium compounds, metal alkoxides, Grignard reagents, hydroxides, phosphates, bisulfates, hydrosulfides, and hydrides.
  • an acid can be used to facilitate synthesizing the azaazulene compounds of the invention.
  • organic or inorganic acid include acetic, benzenesulfonic, benzoic, camphorsulfomc, citric, ethenesulfonic, dichloroacetic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic. hydrochloric, hydrofluoric, hydroiodic, lsethiomc, lactic, maleic, malic, mandehc. methanesulfonic, mucic.
  • a coupling reagent can be used to facilitate synthesizing the azaazulene compounds of the invention.
  • Examples of coupling reagent include BOP, CDI, DCC, DEPBT, DIC, EDCHCl, HATU, HBTU, HCTU, PyBOP, PyBrOP, TATU, TBTU, TDBTU, TSTU and the like.
  • a metal-containing catalyst can be used to facilitate synthesizing the azaazulene compounds of the invention.
  • the metal include Fe. Ni, Co, Cu, Au, Pd, Pt, Rh and Ru.
  • a hgand may exist to facilitate the catalytic ability of the metal
  • a solvent which can be either protic or aprotic.
  • protic solvents include alcohols and water.
  • aprotic solvents include hexane, toluene, benzene, methylene chloride, chloroform, dimethylformamide, dimethyl sulfoxide, and tetrahydrofuran
  • An azaazulene compound thus synthesized can be purified by a suitable method such as column chromatography, high-pressure liquid chromatography, distillation, sublimation or recrystalhzation
  • Other azaazulene compounds can be prepared using other suitable starting materials through the above synthetic routes and others known in the art
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the azaazulene compounds
  • various synthetic steps either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the azaazulene compounds
  • various synthetic steps either before or
  • azaazulene compounds mentioned herein may contain a non-aromatic double bond and one or more asymmetric centers Thus, they can occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, diastereomeric mixtures, and CiS- or trans-isomeric forms All such isomeric forms are contemplated [0065] Also withm the scope of this invention is a pharmaceutical composition containing an effective amount of at least one azaazulene compound described above and a pharmaceutical acceptable carrier
  • an effective amount' ' refers to the amount of an active azaazulene compound that is required to confer a therapeutic effect on the treated subject Effective doses will vary, as recognized by those skilled in the art, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
  • the pharmaceutically acceptable carrier can include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • the azaazulene compounds of the invention are useful for detecting either azaazulene or 6,5-fused heterocycle recognition sites.
  • An azaazulene or 6,5-fused heterocycle recognition site can be any enzyme, receptor, channel, transporter, functional protein, RNA or DNA site that binds to the azaazulene or 6,5-fused heterocycle moiety of an azaazulene compound of the invention.
  • the compounds of the invention can be used as diagnostic agents, prognostic agents, molecular probes, separation tools and therapeutic agents relating to diseases or disorders associated with such an enzyme, receptor, channel, transporter, functional protein, RNA or DNA.
  • Suitable salts for the components to be employed according to the present subject matter are also those with inorganic cations, for example alkali metal salts, in particular sodium, potassium, or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts, as well as salts with bi- or tetravalent cations, for example the zinc, aluminum, or zirconium salts
  • inorganic cations for example alkali metal salts, in particular sodium, potassium, or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts
  • bi- or tetravalent cations for example the zinc, aluminum, or zirconium salts
  • salts with organic bases such as dicyclohexylamme salts. methyl-D-glucamme, and salts with amino acids, such as arginine, lysine, histidme, glutamine and so forth.
  • the basic nitrogen- containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides, such as dec>l, lauryl, mvristyl, and stearyl chlorides, bromides, and iodides, asthma halides, such as benzvl and phenethyl bromides, and others Salt-forming agents, for example, low molecular weight alkylamines such as methylamme, ethylamine, or triethylamine can also be employed Water or oil-soluble or dispersible products are thereby obtained
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides, and
  • a composition having one or more azaazulene compounds can be administered to a subject (e g , a mammal) parenterally, orally, nasally, rectally, topically, or buccally
  • a subject e g , a mammal
  • parenteral refers to subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal. intrathecal, intralesional, or intracranial injection, as well as any suitable infusion technique
  • a sterile injectable composition can be a solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol
  • a non-toxic parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol
  • acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution, and isotonic sodium chloride solution
  • fixed oils are conventionally employed as a solvent or suspending medium (e g , synthetic mono- or diglycerides)
  • Fatty acid, such as oleic acid and its glyceride derivatives are useful in the preparation of mjectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions
  • These oil solutions or suspensions can also contain a long chain alcohol diluent or dispersant, carboxymethyl cellulose, or similar dispersing agents
  • aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added
  • a nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation.
  • such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art
  • a composition having one or more active azaazulene compounds can also be administered in the form of suppositories for rectal administration
  • the carrier in the pharmaceutical composition must be "acceptable” in the sense that it is compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated.
  • One or more solubilizing agents can be utilized as pharmaceutical excipients for delivery of an active azaazulene compound.
  • examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow # 10
  • the invention also provides a method of inhibiting the activity of protein kinase or protein phosphatase in a cell with one of the azaazulene compounds described above.
  • the method includes contacting cells expressing protein kinase or phosphatase with such an azaazulene compound.
  • Protein kinase and phosphatase regulate signaling cascades The cascades in turn regulate cell growth, migration, differentiation, gene expression, muscle contraction, glucose metabolism, cellular protein synthesis, and regulation of the cell cycle.
  • protein kinase'- refers to a kinase enzyme that modifies other proteins by chemically adding phosphate groups to them (phosphorylation)
  • Examples of the protein kinse includes, but are not limited to, AMPK, BLK, CSFlR, FGFR, FGR, FLT3, KDR, KIT, LCK, LYN, MAP4K5, NTRK. PHKGl, RET, SRC, STK, and YESl
  • the cells of the invention can be derived from cancer patients.
  • the cells are also termed “cancer cells” herein.
  • the cells are isolated from a variety of sources and tissues.
  • the cells can be isolated from a blood sample or from a biopsy
  • the cell can be a stem cell, a fibroblast, or a lymphoid cell
  • the cells can be propagated in culture according to cell type and origin of the cells.
  • the cells can be propagated without being immortalized
  • the cells can be immortalized using a virus or a plasmid bearing an oncogene, or a transforming viral protein, e g , papilloma E6 or E7 protein [0079] Table 1. Certain exemplary compounds.
  • B104 1 H-NMR (500 MHz, DMSO-d6) ⁇ (ppm) 11 0 (d, 1H), 9.46 (m, 1H), 7.6 (d, 1H), 7.49 (m, 2H), 7.2-7.51 (m, 3H), 7.01 (b, 2H), 3.69 (m, 4H), 2.79 (q, 1H), 2.71 (b, 4H), 2 05 (b. 2H), 1 84 (b, 4H), 1 25 (s, 2H) [00119] B105, 1 H-NMR (500 MHz, DMSO-d6) ⁇ (ppm) 11 96 (d, 1H), 9 37 (m, 1H),
  • Example 2 [00132] General procedure for the N-Alkylation of B22 and B76 by alkyl halides/alkyl tosylates To a solution of B23 or B76 in CH 3 CN -was added 1 1 eq of diisopropylethylamme followed by 1.2 eq of alkyl hahdes or alkyl tosylates, the reaction mixture was stirred at reflux for 16 h The resulting mixture was allowed to cool to room temperature, concentrated in vacuum, and then purified by silica gel column chromatography to give the compound.
  • DMSO-d6 ⁇ (ppm) 12 13 (s, 1H), 11 69, 11 80 (s, 1H), 9.23, 9 33 (d, 1H), 7.32-7 55 (m, 4H), 7.19-7.26 (m, 1H), 6.96, 7 01 (s, 1H), 6 77 (t, 1H), 6 55 (t, 1H), 3.98 (s, 2H), 3 66 (s, 2H), 3.62 (d, 2H), 2 55 (s, 2H), 2.00 (d, 2H) [00169] B99, 1 H-NMR (500MHz. DMSO-d ⁇ ) ⁇ (ppm) 12.12 (s, 1H), 11.69, 11.81 (s, 1H), 9.25 (s.
  • Example 6 [00181] General procedure for the preparation of urea type compounds Starting material B6 and 1.5 eq isocyanate 22 were mixed in dichloromethane and allowed to react at room temperature for 1 day After working up, the residue was then purified by column chromatography to give the target urea compound
  • B121 1 H-NMR (500MHz, DMSO-d6) ⁇ (ppm) 12.04, 12.06 (s, 1H), 9 31, 9.36 (d, 1H), 8.66, 8.70 (s, 1H), 8 60, 8.63 (s, 1H), 7.84, 7 87 (s, 1H), 7.54-7.61 (m, 2H), 7.44- 7.51 (m, 3H), 7.38 (t, 1H), 7 16-7.30 (m, 4H), 6.96 (t, 1H) [00187] B122. 1 H-NMR (500MHz, DMSO-d6) ⁇ (ppm) 12 11 (s, 1H), 12.20 (s, 1H), 9.63, 9.67 (s, 1H), 9 32.
  • Example 7 [00205] General procedure for the preparation of amide derivatives by couplig acid B7 with amines B7 and 1 5eq of HBTU (2-(1H-Benzotriazole-1-yl)-l, 1 ,3,3- tetramethyluronium hexafluorophosphate) were mixed in dichloromethane in a round- bottomed flask at room temperature. After 10 minutes, 3 eq of amine was added dropwise. The reaction mixture was stirred overnight at room temperature under nitrogen The mixture was diluted with ethyl acetate and washed with sodium carbonate solution The organic layer was separated, dried with anhydrous magnesium sulfate, and then evaporated in vacuum.
  • HBTU 2-(1H-Benzotriazole-1-yl)-l, 1 ,3,3- tetramethyluronium hexafluorophosphate
  • B72 1 H-NMR (500 MHz, DMSO-d6) ⁇ (ppm) 9.39 (d. 2H), 8.51 (s, 2H), 8.24 (s, 1H). 7 82 (d, 1H), 7 59-7 67 (m, 3H), 7 55 (d, 1H), 7 50 (d. 1H), 7 32 (t, 2H), 6 69 (s, 1H), 3 50 (t, 4H), 3.29 (t, 4H). [00208] B73, 1 H-NMR (500 MHz, DMSO-d6) ⁇ (ppm) 12.42 (s, 1H), 12.28 (br, 1H), 10.25 (d, 1H), 9.43 (dd, 1H), 8.02 (dd.
  • Example 11 Kinase Assays [00227] Azaazulene Compounds of this invention were treated for their efficacy in inhibiting activities of FLT-3, c-KIT and KDR kinases by biochemical DELFIA (Dissociation Enhanced Lanthamde FIA) assays according to the procedure descnbed below The assays were conducted bv, Division of Cell Engineering, Biomedical Engineering Research Laboratories, Industrial Technology Research Institute, Bldg 53, 195, sec 4, Chung Hsmg Rd Chutung, Hsinchu, Taiwan 310, R O C [00228] The FLT-3 assay was conducted following the protocol
  • c-KIT assay was conducted following the protocol described in Protocol for HTScan R TM c-KIT Kinase Assay Kit (Cell Signaling Technology 1 *TM). The assay was conducted under the following conditions: c-KIT source: The GST-c-KIT fusion protein was produced using a baculovirus expression system with a construct expressing human c- KIT (Thr544-Val976) with an amino -terminal GST tag, substrate.
  • This biotinylated peptide contains the residues surrounding Tyr-996 of KDR, vehicle: 1% DMSO, preincubation time/temperature 5 minutes at room temperature, incubation time/temperature 30 minutes at room temperature, incubation buffer: 60 mM HEPES pH 7.5, 5 niM MgCk, 5 mM MnCl 2 . 3 uM Na 3 VO 4 , 1.25 mM DTT, 20 uM ATP, and quantitative method: DELFIA. RTM. Assay.
  • the KDR assay was conducted following the protocol described in Protocol for HTScan. R TM VEGFR-2 Kinase Assay Kit (Cell Signaling Technology *TM ). The assay was conducted under the following conditions KDR source
  • the GST-Kinase fusion protein was produced using a baculovirus expression system with a construct expressing human VEGFR-2 (Val789-Vall 356) (GenBank Accession No. NM. sub -002253) with an ammo- terminal GST tag, substrate.
  • the cell line was cultured with RPMI 1640 containing 10% fetal bovine serum, 1 mmol/L sodium pyruvate and 10 mmol/L
  • HEPES (pH 7 4) The cell was grown and maintained in a humidified atmosphere at 37 ° C and 5% carbon dioxide
  • MV4-11 cell was plated in 96-well microtiter plates (10,000 cells per well) and serial dilutions of indicated compounds were added. At the end of the incubation period (72 hours at 37°C), cell viability was determined by a tetrazolium dye, MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazohum bromide) (Promega, Madison, WI) The formazan crystals were dissolved b ⁇ DMSO, and the absorbance at a wavelength of 600 nm was recorded using an ELISA plate reader IC50 values were calculated using nonlinear regression and defined as the concentration needed for a 50% reduction in absorbance of treated versus untreated control cells
  • mice Female BALB/c nude mice (6 to 8 weeks old) were purchased from BioLASCO Co., Ltd (Taipei, Taiwan). Female BALB/c nude mice were implanted subcutaneously in the right flank with I x10 7 MV4-11 (FLT3-ITD) cells per mice.
  • Treatments were initiated when tumors were 150 to 200 mm in size Mice were randomly assigned into cohorts (typically 4 mice per group for efficacy studies) B26 (50 and 150 mg/kg, bid ) and vehicle were given ⁇ ia oral gavage for 14 dajs from the 16 th day after inoculation Tumor volumes were assessed everyday and body weights were assessed two times weekly Caliper measurements of tumors were converted into mean tumor volume using the formula 0 5 x [length x (width) 2 ]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur des composés d'aza-azulène représentés par la formule (I) suivante. Lesdits composés peuvent être utilisés pour moduler les protéines kinases (PK) et/ou traiter le cancer.
EP10769337.6A 2009-04-29 2010-04-29 Composés d'aza-azulène Active EP2491025B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17388309P 2009-04-29 2009-04-29
PCT/CN2010/072342 WO2010124648A1 (fr) 2009-04-29 2010-04-29 Composés d'aza-azulène

Publications (3)

Publication Number Publication Date
EP2491025A1 true EP2491025A1 (fr) 2012-08-29
EP2491025A4 EP2491025A4 (fr) 2013-01-23
EP2491025B1 EP2491025B1 (fr) 2013-11-27

Family

ID=43030852

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10769337.6A Active EP2491025B1 (fr) 2009-04-29 2010-04-29 Composés d'aza-azulène

Country Status (15)

Country Link
US (1) US8492374B2 (fr)
EP (1) EP2491025B1 (fr)
JP (1) JP5538522B2 (fr)
KR (1) KR101278826B1 (fr)
CN (1) CN102405217B (fr)
AU (1) AU2010244019B2 (fr)
BR (1) BRPI1005525A2 (fr)
CA (1) CA2747420C (fr)
ES (1) ES2443870T3 (fr)
IL (1) IL213019A (fr)
MX (1) MX2011006290A (fr)
NZ (1) NZ593004A (fr)
RU (1) RU2524202C9 (fr)
TW (1) TWI410418B (fr)
WO (1) WO2010124648A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5712524B2 (ja) * 2009-10-28 2015-05-07 Jsr株式会社 液晶配向剤および液晶表示素子
KR101852169B1 (ko) 2010-05-20 2018-04-26 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
CN102558096B (zh) * 2010-12-30 2015-01-21 达兴材料股份有限公司 芳香族二胺化合物、使用此芳香族二胺化合物制备的聚酰胺酸与聚酰亚胺以及液晶配向剂
EP3243385B1 (fr) * 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
GB2499666A (en) * 2012-02-27 2013-08-28 Nanyang Polytechnic Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders
JP5949070B2 (ja) * 2012-04-03 2016-07-06 Jsr株式会社 液晶配向剤、液晶配向膜及び液晶表示素子
TWI443096B (zh) 2012-12-18 2014-07-01 Ind Tech Res Inst ３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
CN107108521A (zh) * 2014-10-28 2017-08-29 盐野义制药株式会社 具有ampk活化作用的杂环衍生物
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019034538A1 (fr) * 2017-08-18 2019-02-21 Universität Regensburg Synthèse, pharmacologie et utilisation de nouveaux inhibiteurs sélectifs de la tyrosine kinase 3 de type fms flt3 (flt3)
US10543214B2 (en) * 2017-10-04 2020-01-28 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143994A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
WO2020231739A2 (fr) * 2019-05-10 2020-11-19 Antidote Ip Holdings, Llc Composés et méthodes de traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918277A2 (fr) * 2006-11-01 2008-05-07 Industrial Technology Research Institute Composés d'azulène

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3230234A (en) 1960-05-06 1966-01-18 Sankyo Co Process for the preparation of 2, 3-dihydro-1h-cyclohepta [b] pyrrole-2, 8-dione derivatives and products thereof
US3113950A (en) 1960-05-06 1963-12-10 Sankyo Co Process for the preparation of cyclohepta [b] pyrrol-8(1h)-one derivatives
US3311641A (en) 1963-06-22 1967-03-28 Sankyo Co Hydrohalides of novel cyclohepta[b]-pyrrole derivatives and a process for preparing the same as well as intermediates and process for their preparations
US4337265A (en) 1981-08-21 1982-06-29 Ayerst, Mckenna & Harrison Inc. Cyclohepta[b]pyrrole derivatives
JPH02178263A (ja) 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
DE68926032T2 (de) 1988-12-29 1996-09-05 Seiko Instr Inc Ansteuersystem für ein Anzeigegerät
USRE34198E (en) * 1989-03-10 1993-03-23 Gate Pallet Systems, Inc. Corrugated construction pallet
BR0014843A (pt) 1999-10-19 2002-06-11 Merck & Co Inc Composto, composição farmacêutica, métodos para tratar ou prevenir o câncer em um mamìfero, uma doença em que a angiogênese está implicada, a vascularização retinal, a retinipatia diabética, a degeneração macular relacionada com a idade, doença inflamatória, uma doença ou condição dependente de tirosina quinase e, patologias relacionadas com o osso, processo para fabricar uma composição farmacêutica, e, método para reduzir ou impedir o dano de tecido que segue um evento isquêmico
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001057018A1 (fr) 2000-02-02 2001-08-09 Abbott Laboratories Inhibiteurs d'azaazulene de la p38 map kinase ou du tnf-alpha
EP1317442B1 (fr) 2000-09-11 2005-11-16 Chiron Corporation Derives de quinolinone comme inhibiteurs de tyrosine kinase
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
CN103788089A (zh) * 2003-09-17 2014-05-14 詹森药业有限公司 作为血清素受体调节剂的稠合杂环化合物
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
WO2006015191A2 (fr) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Analogues de lonidamine multicycliques
KR101319122B1 (ko) 2005-05-13 2013-10-23 노파르티스 아게 약물 저항성 암을 치료하는 방법
BRPI0712557A2 (pt) * 2006-05-26 2013-07-02 Novartis Ag inibidores de aldosterona sintase e/ou 11 beta-hidrolase
CN101626786A (zh) 2007-03-01 2010-01-13 马林克罗特公司 整合光敏肽及其应用
RU2009136669A (ru) 2007-03-09 2011-04-20 Новартис АГ (CH) Лечение меланомы
WO2008150899A1 (fr) * 2007-05-29 2008-12-11 Emory University Thérapies combinées pour le traitement du cancer et des maladies inflammatoires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918277A2 (fr) * 2006-11-01 2008-05-07 Industrial Technology Research Institute Composés d'azulène

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010124648A1 *

Also Published As

Publication number Publication date
CN102405217B (zh) 2014-06-11
TWI410418B (zh) 2013-10-01
CA2747420A1 (fr) 2010-11-04
JP5538522B2 (ja) 2014-07-02
EP2491025B1 (fr) 2013-11-27
AU2010244019A1 (en) 2010-11-04
TW201038556A (en) 2010-11-01
IL213019A0 (en) 2011-07-31
EP2491025A4 (fr) 2013-01-23
CA2747420C (fr) 2013-09-10
JP2012524032A (ja) 2012-10-11
AU2010244019B2 (en) 2012-05-10
RU2011122916A (ru) 2013-06-10
CN102405217A (zh) 2012-04-04
RU2524202C2 (ru) 2014-07-27
US20100280012A1 (en) 2010-11-04
NZ593004A (en) 2013-05-31
RU2524202C9 (ru) 2015-06-10
MX2011006290A (es) 2011-09-28
WO2010124648A1 (fr) 2010-11-04
ES2443870T3 (es) 2014-02-20
KR20110098738A (ko) 2011-09-01
IL213019A (en) 2014-07-31
BRPI1005525A2 (pt) 2016-02-23
KR101278826B1 (ko) 2013-06-25
US8492374B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
EP2491025B1 (fr) Composés d'aza-azulène
JP5781934B2 (ja) チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
WO2018045957A1 (fr) Inhibiteur de cdk4/6, son procédé de préparation et son application
EP2298770A1 (fr) Composés hétérocycliques en tant que modulateurs de TrkA
JP6465996B2 (ja) ３−アセチレニル−ピラゾール−ピリミジン誘導体、およびその製造方法およびその使用
JP6594571B2 (ja) マルチキナーゼ阻害剤化合物、並びにその結晶形及びその使用
AU4718997A (en) Fused bicyclic pyrimidine derivatives
KR20130045398A (ko) 피롤로피리미딘 화합물 및 그 용도
JP2016501251A (ja) がんの治療のための新規二環フェニル−ピリジン／ピラジン
JPWO2016208592A1 (ja) 二環性複素環アミド誘導体
EP1918277B1 (fr) Composés d'azulène
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
JP2022526147A (ja) Ｃｄ７３阻害剤、その製造方法と応用
WO2022042612A1 (fr) Dérivé de dihydropyrrolo[2,3-d]pyridazin-7-one, son procédé de préparation et son utilisation
WO2023109158A1 (fr) Composé de 7-méthylthiazolo[5,4-d]pyrimidine, son procédé de préparation et son utilisation
KR101480759B1 (ko) 아자인돌 유도체 화합물, 이를 포함하는 Ｔｒｋ 저해제 조성물 및 Ｔｒｋ와 관련된 질환의 예방 및 치료용 약학 조성물
CN116981662A (zh) 嘧啶-4，6-二胺衍生物及其制备方法和药学上的应用
JP2024510520A (ja) ダブルリング雑環ｆｇｆｒ４阻害剤、ダブルリング雑環ｆｇｆｒ４阻害剤を含有する医薬組成物と製剤、及びその用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20121221

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/14 20060101ALI20121217BHEP

Ipc: A61K 31/41 20060101ALI20121217BHEP

Ipc: A61K 31/403 20060101ALI20121217BHEP

Ipc: C07D 407/14 20060101ALI20121217BHEP

Ipc: C07D 473/34 20060101ALI20121217BHEP

Ipc: A61K 31/435 20060101ALI20121217BHEP

Ipc: A61K 31/40 20060101ALI20121217BHEP

Ipc: C07D 401/04 20060101AFI20121217BHEP

Ipc: A61K 31/4184 20060101ALI20121217BHEP

Ipc: A61P 35/00 20060101ALI20121217BHEP

Ipc: A61K 31/407 20060101ALI20121217BHEP

Ipc: A61K 31/52 20060101ALI20121217BHEP

Ipc: A61K 31/4164 20060101ALI20121217BHEP

Ipc: A61K 31/4188 20060101ALI20121217BHEP

Ipc: C07D 487/04 20060101ALI20121217BHEP

Ipc: A61K 31/437 20060101ALI20121217BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130701

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: ROTTMANN, ZIMMERMANN + PARTNER AG, CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 642649

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010012104

Country of ref document: DE

Effective date: 20140123

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2443870

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140220

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20131127

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 642649

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131127

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140227

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140327

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010012104

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140429

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010012104

Country of ref document: DE

Effective date: 20140828

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140228

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100429

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: GARTENSTRASSE 28 A, 5400 BADEN (CH)

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131127

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240501

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240503

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240422

Year of fee payment: 15

Ref country code: FR

Payment date: 20240425

Year of fee payment: 15